8-K: Albertsons Reports Q3 2025 Results, Updates Outlook

Albertsons Companies reported solid third-quarter fiscal 2025 results, driven by digital and pharmacy growth, while updating its full-year outlook.

Summary

• Identical sales increased 2.4% for the third quarter of fiscal 2025.
• Digital sales grew 21% during the third quarter of fiscal 2025.
• Loyalty members increased 12% to 49.8 million.
• Net sales and other revenue increased 1.9% to $19,123.7 million for the 12 weeks ended November 29, 2025, compared to $18,774.5 million in the prior year.
• Net income was $293.3 million, or $0.55 per share, for the third quarter of fiscal 2025, down from $400.6 million, or $0.69 per share, in the prior year, partly due to a discrete state income tax benefit in the prior year.
• Adjusted net income was $390.3 million, or $0.72 per share, for the third quarter of fiscal 2025, compared to $420.3 million, or $0.71 per share, in the prior year.
• Adjusted EBITDA was $1,038.7 million, or 5.4% of Net sales and other revenue, for the third quarter of fiscal 2025, down from $1,065.1 million, or 5.7%, in the prior year.
• Gross margin rate decreased to 27.4% from 27.9% in the prior year, primarily due to increased delivery and handling costs for digital sales and strong growth in lower-margin pharmacy sales.
• Selling and administrative expenses decreased to 24.9% of Net sales and other revenue from 25.1% in the prior year, driven by sales leveraging of employee costs and lower merger-related costs.
• Capital expenditures for the first 40 weeks of fiscal 2025 were $1,412.8 million, including 74 remodels and 5 new store openings.
• The company repurchased $750 million of common stock through an accelerated share repurchase agreement and increased its share repurchase program authorization to $2.75 billion.
• Issued $1.5 billion in new senior unsecured notes ($700.0 million at 5.500% due 2031 and $800.0 million at 5.750% due 2034) to redeem $750.0 million of 3.250% notes due 2026 and repay ABL facility borrowings.

Sentiment

Score: 6

Explanation: While the company delivered solid identical sales and strong digital growth, indicating operational strengths, the decrease in net income and Adjusted EBITDA, coupled with a lowered full-year outlook for key metrics, suggests some headwinds. Gross margin compression from digital and pharmacy growth, while strategic, impacts profitability. Share repurchases and debt refinancing are positive capital allocation moves, but ongoing litigation and regulatory impacts introduce uncertainty.

Positives

• Identical sales increased 2.4%, primarily driven by strong growth in pharmacy sales.
• Digital sales experienced significant growth of 21% during the quarter.
• Loyalty membership expanded by 12%, reaching 49.8 million members.
• Selling and administrative expenses decreased as a percentage of Net sales and other revenue, indicating improved operational leverage.
• Reported a net gain on property dispositions and impairment losses of $1.2 million, a positive shift from a net loss of $10.2 million in the prior year.
• Increased the share repurchase program authorization to $2.75 billion and executed a $750 million accelerated share repurchase agreement.
• Successfully refinanced debt by issuing new senior unsecured notes to redeem existing notes and repay ABL facility borrowings, optimizing the debt structure.

Negatives

• Net income decreased to $293.3 million from $400.6 million in the prior year, partly due to a higher effective tax rate (22.3% vs. 3.5%) as the prior year included $81.0 million in discrete state income tax benefits.
• Adjusted EBITDA decreased to $1,038.7 million from $1,065.1 million in the prior year.
• Gross margin rate decreased by 50 basis points to 27.4%, primarily due to higher delivery and handling costs related to digital sales growth and the lower gross margin rate of pharmacy sales.
• Identical sales were negatively impacted by an estimated 10 to 20 basis points due to a temporary government shutdown and related delayed SNAP funding.
• Interest expense, net, increased to $116.0 million from $109.0 million in the prior year.
• Updated fiscal 2025 outlook for identical sales growth was lowered to a range of 2.2% to 2.5% (previously 2.2% to 2.75%).
• Updated fiscal 2025 outlook for Adjusted EBITDA was lowered to a range of $3.825 billion to $3.875 billion (previously $3.8 billion to $3.9 billion).

Risks

• Changes in macroeconomic conditions such as rates of food price inflation or deflation, fuel and commodity prices, and macroeconomic uncertainty, including in international trade and current and potential future tariffs.
• Changes in consumer behavior and spending patterns resulting from macroeconomic conditions, including shifts in state and federal assistance programs.
• Changes in wage rates and the ability to negotiate acceptable contracts with labor unions, including the outcome of pending union negotiations.
• Changes in price of goods sold in stores and cost of goods used in food products, as well as limitations in the ability to provide certain services, due to changes in various state and federal government legislation, regulation, and executive orders.
• Uncertainty regarding the geopolitical environment.
• Inability to succeed in a competitive landscape.
• Inability to execute on standalone business and value-creating strategies following the termination of the merger agreement with Kroger due to prolonged uncertainties and restrictions on the business during the pendency of the merger.
• Litigation in connection with the previously pending merger and the termination of the merger agreement, resulting in ongoing costs that may be required to pay in connection with the lawsuit against Kroger, or inability to collect the $600 million termination fee from Kroger, and negative reactions from the financial markets and suppliers, customers, and associates as a result of the litigation.
• Inability to recruit and retain qualified or specialized associates who are critical to the success of the Customers for Life strategy.
• Failure to achieve productivity initiatives, including those related to artificial intelligence, unexpected changes in objectives and plans, inability to implement strategies, plans, programs and initiatives, or enter into strategic transactions, investments or partnerships in the future on terms acceptable, or at all.
• Challenges with the supply chain.
• Operational and financial effects resulting from cyber incidents at the Company or at a third party, including outages in the cloud environment and the effectiveness of business continuity plans during a ransomware or other cyber incident.
• Changes in tax rates, tax laws, and regulations that directly impact the business or customers.
• The Inflation Reduction Act's Medicare Drug Price Negotiation Program, which took effect on January 1, 2026, is expected to result in lower pharmacy sales, impacting identical sales by an estimated 16 to 18 basis points for fiscal 2025 or 65 to 70 basis points for the fourth quarter of fiscal 2025.

Future Outlook

The company provided an updated fiscal 2025 outlook, expecting identical sales growth in the range of 2.2% to 2.5% (previously 2.2% to 2.75%), Adjusted EBITDA in the range of $3.825 billion to $3.875 billion (previously $3.8 billion to $3.9 billion), and Adjusted net income per Class A common share in the range of $2.08 to $2.16 per share (previously $2.06 to $2.19 per share). The effective income tax rate is projected to be 23% to 24% (previously 23.5% to 24.5%), and capital expenditures remain unchanged at $1.8 billion to $1.9 billion. The updated identical sales outlook reflects a 16 to 18 basis point impact for fiscal 2025 (or 65 to 70 basis point impact for the fourth quarter) due to the Inflation Reduction Act's Medicare Drug Price Negotiation Program.

Management Comments

• "In the third quarter, we delivered solid results and continued to advance our strategic priorities." Susan Morris, Chief Executive Officer.
• "Our investments in technology and AI are fundamentally reshaping how we operate and serve our customers; driving smarter decisions, greater efficiency, and more personalized experiences." Susan Morris, Chief Executive Officer.
• "Growth in our digital and pharmacy channels, combined with disciplined execution and targeted investments, is strengthening our value proposition and positioning us for success." Susan Morris, Chief Executive Officer.
• "As we look ahead, I am confident that our modernized technology foundation, relentless focus on productivity, and commitment to innovation will enable us to deliver sustainable long-term value for our customers, associates, and shareholders." Susan Morris, Chief Executive Officer.

Industry Context

Albertsons operates in the highly competitive U.S. food and drug retail sector, where digital transformation and personalized customer experiences are becoming increasingly critical. The company's investments in technology and AI align with broader industry trends aimed at enhancing operational efficiency and customer engagement. The focus on productivity initiatives is essential to mitigate the impact of rising wage rates and inflationary pressures, which are prevalent across the retail industry. The impact of government regulations, such as the Inflation Reduction Act's Medicare Drug Price Negotiation Program on pharmacy sales, highlights the evolving regulatory landscape affecting the sector.

Legal Proceedings

• Litigation in connection with the previously pending merger with Kroger and the termination of the merger agreement, resulting in ongoing costs.
• Potential inability to collect the $600 million termination fee from Kroger.

Stakeholder Impact

• Shareholders are impacted by the updated financial outlook, dividend payments, and the increased share repurchase program. They also face potential risks from ongoing litigation related to the terminated Kroger merger.
• Customers benefit from investments in technology and AI, leading to more personalized experiences and a strengthened value proposition.
• Associates are affected by increasing wage rates and productivity initiatives, with retention programs in place related to the terminated merger.
• Suppliers may experience negative reactions due to the litigation surrounding the terminated merger.
• Creditors are impacted by the company's debt refinancing activities, including the issuance of new senior unsecured notes and the redemption of existing ones.

Next Steps

• The final settlement of the accelerated share repurchase agreement is expected to occur in the first calendar quarter of 2026.
• The next quarterly dividend payment of $0.15 per share is scheduled to be paid on February 6, 2026, to stockholders of record as of January 23, 2026.
• Continue investments in technology and AI to drive smarter decisions, greater efficiency, and more personalized customer experiences.
• Maintain a relentless focus on productivity initiatives to offset increasing wage rates and inflationary pressures.

Key Dates

Recommendation

Albertsons delivered solid Q3 results with strong digital and identical sales growth, indicating operational strength in key areas. However, the slight decline in Adjusted EBITDA and net income, coupled with a downward revision of the full-year outlook for identical sales and Adjusted EBITDA, suggests some headwinds and increased caution. The gross margin pressure from digital and pharmacy growth is a factor to monitor. While the share repurchase program and debt refinancing are positive for shareholder value and financial flexibility, the ongoing litigation related to the terminated Kroger merger and the impact of the Inflation Reduction Act introduce uncertainty. Given the mixed signals and revised outlook, a "hold" recommendation is appropriate as investors await further clarity on the company's ability to navigate these challenges and realize the benefits of its strategic investments.

Keywords

Albertsons, ACI, Q3 2025, earnings, financial results, grocery, retail, supermarket, digital sales, identical sales, EBITDA, net income, share repurchase, debt refinancing, outlook, pharmacy, loyalty, capital expenditures